Susquehanna International Group
ELDN icon

Susquehanna International Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Susquehanna International Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,000
Closed -$19.6K – 13381
2025
Q4 		$19.6K Sell
13,000
-29,500
-69% -$70.1K ﹤0.01% 11966
2025
Q3 		$110K Buy
+42,500
New +$124K ﹤0.01% 11504

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Susquehanna International Group's ELDN Position: Q1 2026 in Review

Susquehanna International Group increased its Eledon Pharmaceuticals (ELDN) stake by 310% in Q1 2026, buying an estimated $196K and bringing the position to 109,949 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #10611.

Susquehanna International Group first reported a position in ELDN in Q4 2014 and has held it in 18 quarters since. The position peaked at $5.38M in Q1 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Susquehanna International Group held 109,949 shares of Eledon Pharmaceuticals worth $339K as of Q1 2026.
  • Susquehanna International Group bought 83,152 Eledon Pharmaceuticals shares in Q1 2026, an estimated $196K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10611 holding.
  • Susquehanna International Group first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 18 quarters since.
  • Susquehanna International Group's Eledon Pharmaceuticals position peaked at $5.38M in Q1 2025.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.